Insider Selling: KALA BIO, Inc. (NASDAQ:KALA) Insider Sells 2,021 Shares of Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $15,420.23. Following the sale, the insider now directly owns 67,807 shares of the company’s stock, valued at approximately $517,367.41. The trade was a 2.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

KALA BIO Trading Down 11.3 %

Shares of KALA BIO stock opened at $6.82 on Thursday. The company has a market capitalization of $31.44 million, a P/E ratio of -0.55 and a beta of -2.11. The stock has a fifty day simple moving average of $6.71 and a 200 day simple moving average of $6.32. KALA BIO, Inc. has a 12-month low of $4.21 and a 12-month high of $9.25. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.43) by $0.50. On average, sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research note on Friday, November 15th.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new position in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. Institutional investors and hedge funds own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.